FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1912068049> ?p ?o ?g. }

• W1912068049 endingPage "2717" @default.
• W1912068049 startingPage "2710" @default.
• W1912068049 abstract "To determine the efficacy, safety, pharmacokinetics, and effect on serum angiogenic growth factors of two dose levels of thalidomide in patients with metastatic breast cancer.Twenty-eight patients with progressive metastatic breast cancer were randomized to receive either daily 200 mg of thalidomide or 800 mg to be escalated to 1,200 mg. Fourteen heavily pretreated patients were assigned to each dose level. Each cycle consisted of 8 weeks of treatment. Pharmacokinetics and growth factor serum levels were evaluated.No patient had a true partial or complete response. On the 800-mg arm, 13 patients had progressive disease at or before 8 weeks of treatment and one refused to continue treatment. The dose was reduced because of somnolence to 600 mg for five patients and to 400 mg for two and was increased for one to 1,000 mg and for four to 1,200 mg. On the 200-mg arm, 12 patients had progressive disease at or before 8 weeks and two had stable disease at 8 weeks, of whom one was removed from study at week 11 because of grade 3 neuropathy and the other had progressive disease at week 16. Dose-limiting toxicities included somnolence and neuropathy. Adverse events that did not require dose or schedule modifications included constipation, fatigue, dry mouth, dizziness, nausea, anorexia, arrhythmia, headaches, skin rash, hypotension, and neutropenia. Evaluation of circulating angiogenic factors and pharmacokinetic studies failed to provide insight into the reason for the lack of efficacy.Single-agent thalidomide has little or no activity in patients with heavily pretreated breast cancer. Further studies that include different patient populations and/or combinations with other agents might be performed at the lower dose levels." @default.
• W1912068049 created "2016-06-24" @default.
• W1912068049 creator A5005514971 @default.
• W1912068049 creator A5008042908 @default.
• W1912068049 creator A5021514634 @default.
• W1912068049 creator A5023081058 @default.
• W1912068049 creator A5027246538 @default.
• W1912068049 creator A5028539104 @default.
• W1912068049 creator A5036496025 @default.
• W1912068049 creator A5037103180 @default.
• W1912068049 creator A5046031005 @default.
• W1912068049 creator A5055830608 @default.
• W1912068049 creator A5069582641 @default.
• W1912068049 creator A5069748055 @default.
• W1912068049 creator A5070245248 @default.
• W1912068049 creator A5071176191 @default.
• W1912068049 creator A5084241748 @default.
• W1912068049 date "2000-07-14" @default.
• W1912068049 modified "2023-09-24" @default.
• W1912068049 title "Phase II Evaluation of Thalidomide in Patients With Metastatic Breast Cancer" @default.
• W1912068049 cites W1568733499 @default.
• W1912068049 cites W1895946034 @default.
• W1912068049 cites W1972764852 @default.
• W1912068049 cites W1974520996 @default.
• W1912068049 cites W1974552575 @default.
• W1912068049 cites W1976195989 @default.
• W1912068049 cites W1978139448 @default.
• W1912068049 cites W1981657376 @default.
• W1912068049 cites W1985147506 @default.
• W1912068049 cites W1989339760 @default.
• W1912068049 cites W1989496327 @default.
• W1912068049 cites W1990499405 @default.
• W1912068049 cites W2021279972 @default.
• W1912068049 cites W2026338689 @default.
• W1912068049 cites W2034485049 @default.
• W1912068049 cites W2037761545 @default.
• W1912068049 cites W2053608262 @default.
• W1912068049 cites W2071525349 @default.
• W1912068049 cites W2075017432 @default.
• W1912068049 cites W2080266291 @default.
• W1912068049 cites W2080713267 @default.
• W1912068049 cites W2093915140 @default.
• W1912068049 cites W2122596233 @default.
• W1912068049 cites W2126237672 @default.
• W1912068049 cites W2159746652 @default.
• W1912068049 cites W2162559503 @default.
• W1912068049 cites W2313493986 @default.
• W1912068049 cites W2316160054 @default.
• W1912068049 cites W2319962899 @default.
• W1912068049 cites W2338946788 @default.
• W1912068049 cites W2395723318 @default.
• W1912068049 cites W2417793136 @default.
• W1912068049 cites W4322382463 @default.
• W1912068049 doi "https://doi.org/10.1200/jco.2000.18.14.2710" @default.
• W1912068049 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10894870" @default.
• W1912068049 hasPublicationYear "2000" @default.
• W1912068049 type Work @default.
• W1912068049 sameAs 1912068049 @default.
• W1912068049 citedByCount "110" @default.
• W1912068049 countsByYear W19120680492012 @default.
• W1912068049 countsByYear W19120680492013 @default.
• W1912068049 countsByYear W19120680492014 @default.
• W1912068049 countsByYear W19120680492015 @default.
• W1912068049 countsByYear W19120680492016 @default.
• W1912068049 countsByYear W19120680492017 @default.
• W1912068049 countsByYear W19120680492018 @default.
• W1912068049 countsByYear W19120680492020 @default.
• W1912068049 countsByYear W19120680492021 @default.
• W1912068049 crossrefType "journal-article" @default.
• W1912068049 hasAuthorship W1912068049A5005514971 @default.
• W1912068049 hasAuthorship W1912068049A5008042908 @default.
• W1912068049 hasAuthorship W1912068049A5021514634 @default.
• W1912068049 hasAuthorship W1912068049A5023081058 @default.
• W1912068049 hasAuthorship W1912068049A5027246538 @default.
• W1912068049 hasAuthorship W1912068049A5028539104 @default.
• W1912068049 hasAuthorship W1912068049A5036496025 @default.
• W1912068049 hasAuthorship W1912068049A5037103180 @default.
• W1912068049 hasAuthorship W1912068049A5046031005 @default.
• W1912068049 hasAuthorship W1912068049A5055830608 @default.
• W1912068049 hasAuthorship W1912068049A5069582641 @default.
• W1912068049 hasAuthorship W1912068049A5069748055 @default.
• W1912068049 hasAuthorship W1912068049A5070245248 @default.
• W1912068049 hasAuthorship W1912068049A5071176191 @default.
• W1912068049 hasAuthorship W1912068049A5084241748 @default.
• W1912068049 hasConcept C112705442 @default.
• W1912068049 hasConcept C121608353 @default.
• W1912068049 hasConcept C126322002 @default.
• W1912068049 hasConcept C141071460 @default.
• W1912068049 hasConcept C197934379 @default.
• W1912068049 hasConcept C2775930923 @default.
• W1912068049 hasConcept C2776364478 @default.
• W1912068049 hasConcept C2776694085 @default.
• W1912068049 hasConcept C2777054765 @default.
• W1912068049 hasConcept C2777063308 @default.
• W1912068049 hasConcept C2778570526 @default.
• W1912068049 hasConcept C2778822529 @default.
• W1912068049 hasConcept C2779034229 @default.
• W1912068049 hasConcept C2779609412 @default.

• next